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Abstract 
Antimicrobial peptides are one of the most promising peptide-based drugs due to their enormous potential as 
novel biopharmaceuticals in both human and animal industries. In order to develop strategies to over produce such 
molecules, heterologous production of a modified version of clavanin A, here named clavanin MO (clavMO), was suc-
cessfully achieved in the methylothopic yeast Pichia pastoris. ClavMO was fused to thioredoxin as a carrier protein and 
the construction was tested using two promoters, PAOX1 and PGAP, based on either induced or constitutive expression 
systems, respectively. After growth in 5 L Bioreactor, clavMO-thio was recovered and purified through size exclusion 
chromatography. Our findings show that both constitutive and inducible expression systems produce active clavMO 
fused to thioredoxin against both Gram-negative Klebsiella pneumoniae and Gram-positive Staphylococcus aureus 
microorganisms.
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Introduction
Antimicrobial peptides (AMPs) are one of the most 
promising peptide-based drugs due to their enormous 
potential as novel biopharmaceutical compounds for the 
human and animal health industries as well as for their 
application in agriculture (Agyei and Danquah 2011; 
Mulder et  al. 2013a; Silva et  al. 2011a). The increase in 
interest over these molecules has driven researchers to 
explore alternatives to chemical synthesis for its large-
scale production. The production of AMPs using heter-
ologous systems has many advantages, such as allowing 
post-translational modification and permitting research-
ers to develop the best genetic strategy to increase its 
production, and most importantly, there is an extensive 
flexibility in microbial systems to be modified and scale-
up (Mulder et al. 2013b). The heterologous expression of 
AMPs has been reported to be successfully performed in 
diverse organisms such as bacteria, plants and yeast (Par-
achin et al. 2012).
Among these organisms, the methylotrophic yeast 
Pichia pastoris has been a promising candidate for the 
heterologous production of AMPs. It has been used for 
the production of AMPs derived from different sources 
such as humans (Hong et  al. 2007; Kim et  al. 2009), 
mammals (Tang et al. 2012; Zhao and Cao 2012), plants 
(Cabral et  al. 2003; Kant et  al. 2009), bacteria (Basanta 
et  al. 2010; Jimenez et  al. 2014) and fungi (Varnai et  al. 
2014; Viragh et  al. 2014). From its initial usage in the 
early 1970s, throughout its complete genome sequence 
(De Schutter et  al. 2009; Mattanovich et  al. 2009), to 
today, P. pastoris has become one of the most extensively 
studied yeasts and presents a versatile system for the pro-
duction of heterologous proteins (Ahmad et  al. 2014). 
The most common expression vectors use a genetic con-
struction based on either alcohol oxidase I (AOX1) or 
glyceraldehyde-3-phosphate dehydrogenase (GAP) pro-
moters, named PAOX1 and PGAP, respectively (Ellis et  al. 
1985; Waterham et al. 1997). PAOX1 is a potent and tightly 
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regulated methanol-inducible promoter; therefore it 
allows for the controlled expression of foreign proteins, 
especially when they are toxic to the host. PGAP is consti-
tutive, and one of its reported advantages is that it simpli-
fies cultivation by avoiding the addition of methanol as a 
carbon source (Zhang et  al. 2009). For instance, human 
cathelicidin (hCAP18) (Hong et al. 2007) and corn defen-
sin (PDC1) (Kant et  al. 2009) have been expressed in P. 
pastoris using a constitutive promoter system. On the 
other hand, many AMPs have been produced using the 
AOX1 promoter system reaching over 1 g g−1 of dry cell 
weight (DCW), as was recently reviewed (Parachin et al. 
2012).
The AMP used in this work was clavanin MO (clavMO) 
(Silva et  al. 2011b), a synthetic variant of amphipathic 
alpha-helical peptide clavanin A (clavA). ClavA was first 
isolated from hemocytes of the tunicate Styela clava. 
The peptide clavA presents, among its 23 residues, stra-
tegically placed histidine residues which provide its pH-
dependent antimicrobial activity, as well as glycine and 
phenylalanine residues which confer to this peptide a 
relative conformational flexibility and hydrophobicity, 
thus facilitating its insertion into the target membrane 
(van Kan et al. 2003b). ClavMO is 5 amino acid residues 
longer than clavA, and it has been shown to have higher 
antibacterial activity against both Gram-negative Kleb-
siella pneumoniae and Gram-positive Staphylococcus 
aureus. Furthermore, clavMO has also presented immu-
nomodulatory, antitumor and antiviral activities (Silva 
et al. 2011b).
Due to its high potential as a new antimicrobial peptide, 
a large amount of clavMO is currently required for the 
production of different drug-delivery systems. Therefore, 
the aim of this study was to establish a system for large-
scale production of heterologous clavMO in P. pastoris. 
For that, two promoters, PAOX1 and PGAP were tested 
based on two expression systems, induced and consti-
tutive, respectively. ClavMO was fused to thioredoxin 
as a carrier protein, chosen for its properties of increas-
ing both stability and solubility of heterologous proteins 
(Esposito and Chatterjee 2006). Our findings show that 
the induced system produces active clavMO against the 
microorganisms K. pneumoniae and S. aureus.
Materials and methods
Strains and plasmids
Bacterial strains and plasmids used in this work are pre-
sented in Table 1. The strains were grown at 37°C in Luria 
broth medium (0.5% Yeast extract, 1% Peptone and 1% 
Sodium Chloride), and the yeast strains were grown at 
28°C in either YPD (0.5% Yeast extract, 1% Peptone and 
2% Dextrose) or BMGY media (2% Peptone, 1% Yeast 
extract, 100 mM Potassium phosphate pH 6, 1.34% Yeast 
Nitrogen Base (w/o AA), 0.4 µg/mL Biotin, 1% Glycerol). 
When necessary, the media were supplemented with 
the appropriate antibiotics (ampicillin for Escherichia 
coli cultivations at 100 µg/mL, and zeocin for P. pastoris 
cultivation at 100  µg/mL). The gene containing the car-
rier protein thioredoxin fused to the peptide clavMO 
was cloned into both expression vectors pPICZαA and 
pGAPZαB, under the methanol-inducible PAOX1 pro-
moter and the constitutive PGAP promoter, respectively.
Cloning
The thio-clavMO gene sequence was synthesized by 
Epoch Life Science (Additional file 1: Figure S1). To clone 
the gene into both plasmids pPICZαA and pGAPZαB, the 
restriction sites EcoRI and SacII were used, resulting in 
the expression vectors pPICZαA-clavMO and pGAPZαB-
clavMO (Figure  1; Table  1). Both plasmids were firstly 
Table 1 Strain and plasmids used in this work
Strain and plasmids Genotype Reference
Strains
 E coli
  XL1-Blue EndA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44  





  X33 Wild type
  X33/pPICZαA-clavMO X33 transformed with the plasmid pPICZαA-clavMO This work
  X33/pGAPZαB-clavMO X33 transformed with the plasmid pGAPZαB-clavMO This work
Plasmids
 pPICZα A Fator-α as secretion signal, AOX1 promotor, bler
 pGAPZα B Fator-α as secretion signal, PGAP promotor, ble
r
 pPICZαA-clavMO pPICZαA with the gene coding for the cassette thioredoxin-clavanin MO This work
 pGAPZαB-clavMO pGAPZαB with the gene coding for the cassette thioredoxin-clavanin MO This work
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transformed into E. coli XL1-Blue strains and sequenced 
to confirm the insertion of the expression cassette.
Yeast transformation
The vectors whose constructions were confirmed by 
sequencing were inserted into the P. pastoris X-33 strain 
using the electroporation method as described by Inv-
itrogen™. Briefly, cells of the X-33 strain were grown in 
solid YPD at 28°C for 2–3 days. A single colony was then 
grown in 5 mL of YPD overnight at 30°C at 250 rpm. 0.1 
to 0.5 mL of this culture was inoculated into 100 mL of 
YPD and grown at 30°C at 250  rpm until an OD600 of 
1.3–1.5 was reached. The cells were centrifuged at 1,500g 
for 5 min and washed three times with ice-cold distilled 
water and then resuspended in 1  M cold sorbitol. Plas-
mids to be inserted in P. pastoris were linearized with 
AvrII and BglII for pGAP and pPIC, respectively. About 
10 μg of linearized DNA was added to 80 μL of compe-
tent cells and 320 μL of 1.0 M sorbitol. Electrical shock 
using 0.2  cm cuvette was performed using Gene Pul-
ser II (Biorad). After electric shock, 1  mL of 1  M cold 
sorbitol was added to the cells followed by incubation at 
30°C. After 1  h of incubation, cells were plated in solid 
YPD medium supplemented with zeocin 100 µg/mL and 
stored at 28°C for 2–3 days.
Evaluation of clavMO production
In order to evaluate the production of clavMO 
in both plasmids, a single colony from each X33/
pPICZαA-clavMO and X33/pGAPZαB-clavMO (Table 1) 
was inoculated into YPD medium at 28°C and cultivated 
overnight at 200 rpm of agitation. Both strains were inoc-
ulated in 100  mL BMGY to reach an OD600 of 0.2 and 
grew for 96 h. Samples were collected at times 0, 24, 48, 
70  h. The pPICZαA-clavMO strain was induced every 
24 h with methanol 100% to a final concentration of 0.5% 
in order to induce the gene encoding for clavMO cloned 
under the AOX1 promoter.
Protein quantification, SDS‑PAGE and immunoblot assays
Protein quantification was performed by using Qubit-
Invitrogen™ according to manufacturer’s instructions. 
For the Western blot and SDS-PAGE experiments, 
150  µg/mL of protein from cultured supernatant was 
collected by the TCA (trichloroacetic acid) precipita-
tion method using TCA at 75%. The pellet was washed 
twice with ice-cold acetone and dissolved in 25 μL 3× 
Laemmli buffer (Laemmli 1970), boiled for 10 min, cen-
trifuged briefly and loaded onto an SDS-PAGE gel using 
protein molecular weight (Thermo Scientific™). SDS-
PAGE was silver stained as previously described (Blum 
et al. 1987). In order to detect proteins, the protein sam-
ples were first separated by SDS-PAGE and then trans-
ferred under semi-dry conditions onto a nitrocellulose 
membrane using electroblotting (Towbin et  al. 1979). 
The electrophoretic transfer of proteins was performed 
in the Trans-Blot SD (Biorad) and carried out for 15 min 
at 13 V, 3 A and 300 mA using Blotting buffer (3 g Tris, 
14 g glycine, 20% (v/v) methanol, 0.1% (w/v) SDS). After 
transference, membrane blocking was achieved by incu-
bation in AP-T buffer (1 M Tris/HCl pH 7.4, 1 M NaCl, 
25  mM MgCl2, 0.03% (v/v) Tween 20) containing 5% 
(w/v) milk powder. The following steps were then carried 
out only in AP-T buffer. The procedure for detection of 
labeled proteins was performed using polyclonal anti-
bodies against thioredoxin (1:5,000) and revealed using 
BCIP/NBT solution, according to the manufacturer’s 
protocol.
Growth of X‑33 pPicZ‑clavMO in 5 L Bioreactor
The strain X-33/pPic-clavMO was grown in a 5 L biore-
actor (Bio Flo115, New Brunswick). For cultivation in the 
bioreactor, BMGY media was used containing 40  g  l−1 
glycerol. Pre-growth was performed in 100  mL BMGY 
shake flasks for 30 h. The cells were centrifuged and inoc-
ulated in the bioreactor to reach an initial OD600 of 0.5. 
Glycerol was used for 24 h of growth, after which metha-
nol was fed into the bioreactor for a final concentration 
of 0.5% every 12 h up to 72 h. At the end of the fermenta-
tion, 5 L culture medium was centrifuged at 10,000 rpm 
for 10  min. The supernatant was concentrated 10-fold 
using Quickstand (GE Healthcare Life Sciences) by 
Figure 1 Plasmid vector map. The constitutive system was devel-
oped using the plasmid pGAPZαB, which contains the PGAP promoter. 
The inducible system was constructed using the pPICZαA, which 
contains the PAOX promoter. HIS his-tag, Trx thioredoxin E. coli gene, 
Cla clavanin gene, AOX TT terminator.
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diafiltration using hollow fiber cartridge with a cut-off of 
3,000 NMWC.
Peptide isolation
Concentrated supernatant from the culture of the strain 
X-33/pPic-clavMO containing 5  mg/mL of protein 
extract was lyophilized and injected into a size exclusion 
chromatography Äkta purifier (GE Healthcare). The col-
umn utilized was the Hiload™ 16/60 Superdex™ 75 prep 
grade column (GE Healthcare). This was equilibrated 
with filtered and degassed water MilliQ at room temper-
ature. The flow rate utilized was 0.8  mL/min. Fractions 
were eluted with 5  mL volumes, totaling 22 fractions. 
These were monitored at 216 and 280  nm for 270  min. 
The fractions from 16 to 22 were lyophilized and used for 
further antibacterial assays.
Antibacterial assays
The antibacterial assays were carried out by microdilu-
tion assay using an Elisa reader for 96-well microplates 
(Biotek, USA). Microdilution assays were performed 
according to the standards of the CLSI (Clinical Labo-
ratory Standards Institute) (2010; 2012). Antimicrobial 
activity assays were performed using K. pneumoniae 
(ATCC13883) and S. aureus (ATCC25923). For each 
assay, chloramphenicol (30 µg/mL) was used as positive 
control (C+) and MH broth at pH 7.3 as a negative con-
trol. Bacterial growth was monitored every 30 min until 
it reached the stationary phase (about 24  h). The pro-
tein fractions 16–22 were utilized in a concentration of 
120 µg/mL. Percentage of bacterial growth inhibition val-
ues was based on the absorbency values at 625 nm, which 
were compared with the values obtained for C+ (repre-
senting 100% bacterial growth inhibition). All antibacte-
rial assays were performed in triplicate.
Results
Production of clavMO
X-33/pPICZαA-clavMO and X-33/pGAPZαB-clavMO 
were selected for growth experiments and heterolo-
gous peptide production. P. pastoris containing the 
constitutive expression cassette, pGAPZαB-clavMO, 
resulted in about 1.5-fold lower final OD when com-
pared to the strain containing the inducible expression 
cassette pPICZαA-clavMO (Figure  2). Therefore for the 
evaluation of antibacterial activity of clavMO the strain 
pPICZαA-clavMO was chosen.
Analysis of recombinant clavMO by Western blot
Supernatant of the strains X33/pPICZαA-clavMO and 
X33/pGAPZαB-clavMO were collected at 0, 24, 48 and 
70 h. Samples of 150 µg/mL from supernatant from the 
culture were applied into an SDS-PAGE (12%) prior 
Western blot assay. According to the results obtained, it 
can be observed that the expression of the recombinant 
clavMO was detected at 48 and 70 h in both strains while 
no recombinant protein was detected prior induction 
with Methanol (Figure  3). It was also observed that the 
appropriated time for induction of the promoter AOX1 
in the X33/pPICZαA-clavMO strain was after 30 h when 
all initial glycerol was entirely consumed (Figure 3, lower 
panel), as well as the constitutive expression of the pro-
moter PGAP for production of the recombinant clavMO 
in the X33/pGAPZαB-clavMO strain (Figure  3, upper 
panel). The predicted size of Thioredoxin-ClavMO fused 
gene was 34.47717 kDa (http://web.expasy.org/compute_
pi/). Our Western blot results show that the detected 
protein correspondent to our expression cassette was 
between 35 and 40 kda (Figure 3), therefore, bigger than 
the predicted MW.
Figure 2 Growth of P. pastoris strains X33/pPICZαA-clavMO (PAOX, 
triangle) and X33/pGAPZαB-clavMO (PGAP, square). Growth was moni-
tored by OD600 every 24 h. Methanol (0.5%) was added to P. pastoris 
strain X33/pPICZαA-clavMO after 30 h of growth. Experiments were 
done in triplicate where figure shows the growth profile within 10% 
standard deviation.
Figure 3 Western blot assay of the supernatant of the strains X33/
pGAPZαB-clavMO (upper panel) X33/pPICZαA-clavMO (lower panel). 
Samples were collected at times 0, 24, 48 and 70 h. MW molecular 
weight (kD). Antibody anti-his tag 1:5,000
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Purification
Figure 4 shows the profile of the P. pastoris supernatant 
containing X33/pPICZαA-clavMO after 70  h of cultiva-
tion. From purification of 5 mg/mL of protein extract into 
a size exclusion chromatography, seven fractions were 
collected, numbered 16–22, and were selected for further 
analysis. After lyophilization, these samples were used to 
perform antibacterial assays, and two fractions, 21 and 
22, were shown to have antibacterial activity. SDS-PAGE 
analyses of theses samples had shown the protein band 
corresponding to the molecular mass of clavMO but with 
different purity degrees (Figure 4).
Antibacterial assays
Preliminary bioassays revealed that some fractions 
showed low protein quantification and no antibacterial 
activity. Therefore, the fractions ranging from 16 to 22 
were chosen for antibacterial bioassay due to their higher 
absorbance at 280 nm. Bioassays were performed against 
Gram-negative K. pneumoniae and Gram-positive S. 
aureus bacteria. For each bioassay, 120  µg/mL of X-33/
pPic-clavMO protein was used in triplicate. The bioassay 
against K. pneumoniae showed antibacterial activity for 
fraction 21 and 22 where bacterial growth was reduced 
by 56 and 8%, respectively (Table 2). On the other hand, 
the bioassay performed against S. aureus showed anti-
bacterial activity for fractions 21 and 22 where bacte-
rial growth was inhibited by 68 and 89%, respectively 
(Table 2).
Discussion
Heterologous production of antimicrobial peptides has 
been attempted in several hosts over the last few years. 
After the bacterium Escherichia coli, yeasts are the sec-
ond most used system for heterologous peptide produc-
tion (Parachin et  al. 2012). In this study, heterologous 
production of a modified clavanin fused to thioredoxin, 
clavMO-thio, was initially attempted in different E. coli 
strains. Nevertheless, expression of the encoding gene 
could never be confirmed (Additional file  2: Figure S2, 
Additional file  3: Figure  S3 and Additional file  4: Fig-
ure  S4). The same has been previously observed when 
the production of SPE10 isolated from the Pachyrrhizus 
erosus peptide was attempted in both E. coli and P. pas-
toris where heterologous peptide production could only 
be confirmed when produced in yeast (Song et al. 2005).
Figure 4 Chromatogram profile of supernatant of strain X-33/pPic-clavMO. 5 mg/mL of protein extract using a Hiload™ 16/60 Superdex™ 75 prep 
grade column (GE Healthcare) originating 24 fractions eluted in approximately 5 mL and monitored at 280 nm. The silver-stained gel shows the 
protein recovered from fractions 21 and 22 after purification process. MW molecular weight (kD).
Table 2 Antibacterial assay against  K. pneumoniae and  S. 
aureus using 120  µg/mL of  X-33/pPic-clavMO protein 
for 24 h at absorbance λ = 625 nm
Values were represented by mean ± standard deviation. Chloramphenicol 















21 56 ± 1.4 68 ± 1.7
22 8 ± 1.2 89 ± 1.4
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Although Sacharomyces cerevisiae is the most com-
mon yeast utilized for biopharmaceutical production, 
the yeast P. pastoris was chosen as the host in this 
study for having a GRAS (Generally Regards As Safe) 
status, the ability to grow in high cell density cultures 
(since it does not present fermentative behavior), and 
its reported high levels of secreted recombinant protein, 
which simplifies downstream purification processes 
(Ahmad et  al. 2014). Finally, most recombinant AMPs 
produced in yeast use P. pastoris as a host (Parachin 
et al. 2012).
Although some companies claim the production of 
recombinant clavanins isoforms such as B, C, D and 
E using both S. cerevisiae and E. coli as hosts, herein 
we report for the first time the heterologous produc-
tion of clavanin using P. pastoris as a host to express 
clavMO. Synthetic ClavMO is reported to have higher 
antibacterial activity against both Gram-positive (e.g., 
78.75 µM against S. aureus ATCC29213; 2.5-fold higher 
than synthetic clavA) and Gram-negative bacteria 
(e.g. 39.40  µM against K. pneumoniae—ATCC13885; 
2.5-fold higher than synthetic clavA). Furthermore, 
clavMO has also presented immunomodulatory, anti-
tumor, antiviral and insecticide activities (Silva et  al. 
2011b).
In this study Clav-MO fused to thioredoxin in its 
N-terminal presented antibacterial activity. Although 
one could argue that thioredoxin could have inhibitory 
activity by itself its gene sequence was from the E. coli 
genome where it has been previously described its role 
in defense against oxidative stress or in control of apop-
tosis (Arnér and Holgren 2000). Moreover thioredoxin 
is frequently used as a carrier protein for production of 
recombinant antimicrobial peptide representing more 
than 20% of all reported fusion expressions of antimicro-
bial peptides (Li 2009). Finally, in a study for heterolo-
gous production of viscotoxin where 13 fusion proteins 
were tested, thioredoxin gave the highest yield of soluble 
protein (Bogomolovas et al. 2009). For all those reasons 
we claimed that the activity against the microorganisms 
tested in our work is derived from the activity of the 
peptide clav-MO.
Here we demonstrate the production of a heterolo-
gous AMP using both constitutive and inducible pro-
moters. Few of the reported studies used a constitutive 
promoter to express gene encoding for AMPs (Guo 
et al. 2012; Hong et al. 2007; Yu et al. 2010). Constitu-
tive AMP production is advantageous as the fermenta-
tion process is facilitated because there is no need for 
additional inductor or media exchange. Nevertheless, 
if the AMP has antifungal activity, the use of such a 
promoter is not advisable, for it impairs yeast growth 
and consequently heterologous AMP production. In 
all reported cases, the amount of heterologous pep-
tide produced using constitutive promoter was not 
reported. Moreover, in this study the strain with con-
stitutive cassette had a negative impact on final OD, 
which corroborates previous studies and reinforces the 
utilization of inducible constructions for heterologous 
production of AMP.
Regarding clavanin mode of action, it is known that its 
bactericide activity is related to membrane stability in a 
pH dependent form (van Kan et  al. 2001, 2002, 2003a). 
Furthermore, clavanin A has been shown to interact with 
lipid bi-layers, resulting in drastic changes in membrane 
morphology (van Kan et al. 2003b). Recently, our group 
has shown that nanoformulated clavanin A inhibit bacte-
rial growth of S. aureus, K. pneumoniae and Pseudono-
mas aeruginosa, being an excellent candidate for treating 
patients contaminated with antibiotic-resistant bacteria 
(Saúde et  al. 2014). Another work form our group has 
shown that clavanin A is effective in treatments of wound 
and sepsis infections by avoiding the beginning of sep-
sis, and as consequence, it reduces mortality (Silva et al. 
2015).
Nevertheless, the chemical synthesis of clavanin aim-
ing at nanoformulation is not cost-effective. In this study, 
recombinant clavMO was shown to inhibit both Gram-
positive and Gram-negative bacteria. Thus, it presents an 
initial step for the development of cost-effective, large-
scale production of this AMP.
In this study, for the first time, the modified version 
of clavanin A, clavMO was heterologously produced 
in P. pastoris using both constitutive and inducible 
expression cassettes. Both systems yielded protein 
detection in yeast supernatant by Western blot assays. 
The strain with integrated constitutive construc-
tion resulted in lower final OD when compared to the 
strain with the inducible construction integrated in 
its genome. Therefore, the strain producing clavMO 
after induction with metanol was chosen for the fol-
lowing experiments. ClavMO was produced in a 5  L 
scale followed up by purification using gel filtration. 
Finally, antimicrobial assays showed that recombinant 
clavMO could inhibit up to 56 and 89% Gram-negative 
and Gram-positive bacteria, respectively. Conclusively, 
it is evident that P. pastoris is an excellent host for the 
functional production of clavMO, and that this sys-
tem may be utilized for further scale-up production of 
AMPs.
Page 7 of 8Mulder et al. AMB Expr  (2015) 5:46 
Abbreviations
AMP: antimicrobial peptide; ClavMO: clavanin modified; ClavA: clavanina A; 
AOX1: alcohol oxidase I; GAP: glyceraldehyde-3-phosphate dehydrogenase.
Authors’ contributions
All authors have equally contributed to this work and have read and approved 
the final manuscript.
Author details
1 Centro de Análises Proteômicas e Bioquímicas, Pós-Graduação em Ciências 
Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, DF, Bra-
zil. 2 Grupo Engenharia de Biocatalisadores, Departamento de Biologia Celular, 
Instituto de Ciências Biológicas, Universidade de Brasília, Brasília, DF CEP 
70.790-900, Brazil. 3 S-Inova, Pós-Graduação em Biotecnologia, Universidade 
Católica Dom Bosco, Campo Grande, MS, Brazil. 
Acknowledgements
The National Counsel of Technological and Scientific Development (CNPq), 
the Coordination for the Improvement of Educational Personnel (CAPES), the 
Foundation for Research Support of the Federal District (FAPDF), the Founda-
tion for Educational, Research and Technology of Mato Grosso do Sul (FUN-
DECT), and the Ministry of Science and Technology (MCT) are acknowledged 
for financial support.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 1 June 2015   Accepted: 7 July 2015
References
Agyei D, Danquah MK (2011) Industrial-scale manufacturing of pharmaceuti-
cal-grade bioactive peptides. Biotechnol Adv 29(3):272–277
Ahmad M, Hirz M, Pichler H, Schwab H (2014) Protein expression in Pichia 
pastoris: recent achievements and perspectives for heterologous protein 
production. Appl Microbiol Biotechnol 98(2):5301–5317
Arnér ES, Holgren A (2000) Physiological functions of thioredoxin and thiore-
doxin reductase. Eur J Biochem 267(20):6102–6109
Basanta A, Gómez-Sala B, Sánchez J, Diep DB, Herranz C, Hernández PE 
et al (2010) Use of the yeast Pichia pastoris as an expression host for 
secretion of enterocin L50, a leaderless two-peptide (L50A and L50B) 
bacteriocin from Enterococcus faecium L50. Appl Environ Microbiol 
76(10):3314–33124
Blum H, Beier H, Gross HJ (1987) Improved silver staining of plant-proteins, 
RNA and DNA in polyacrylamide gels. Electrophoresis 8(2):93–99
Bogomolovas J, Simon B, Sattler M, Stier G (2009) Screening of fusion partners 
for high yield expression and purification of bioactive viscotoxins. Protein 
Expr Purif 64(1):16–23
Additional files
Additional file 1: Figure S1. DNA nucleotide sequence for thiore-
doxin and clavMo (underlined). Start codons of both carrier and peptide 
sequence are indicated in bold. Stop codon is highlighted in red
Additional file 2: Figure S2. A) Expression vector pET21a(+) used as 
backbone to insert the expression cassette; B) Expression cassette com-
prised of a signal sequence (Ss), a HIS-tag, the thioredoxin gene end the 
ClavMO peptide. In the white boxes are presented the restriction sites
Additional file 3: Figure S3. Western blot analysis of the superna-
tant fraction of lysed E. coli strains. A) pLyzS/pET21-clavMO, B) pRIL/
pET21-clavMO
Additional file 4: Figure S4. Western blot analysis of the pellet cell frac-
tion of lysed E. coli strains. A) pLyzS/pET21-clavMO, B) pRIL/pET21-clavMO
Cabral KM, Almeida MS, Valente AP, Almeida FC, Kurtenbach E (2003) Produc-
tion of the active antifungal Pisum sativum defensin 1 (Psd1) in Pichia 
pastoris: overcoming the inefficiency of the STE13 protease. Protein Expr 
Purif 31(1):115–122
De Schutter K, Lin YC, Tiels P, Van Hecke A, Glinka S, Weber-Lehmann J et al 
(2009) Genome sequence of the recombinant protein production host 
Pichia pastoris. Nat Biotechnol 27(6):561–566
Ellis SB, Brust PF, Koutz PJ, Waters AF, Harpold MM, Gingeras TR (1985) Isolation 
of alcohol oxidase and two other methanol regulatable genes from the 
yeast Pichia pastoris. Mol Cell Biol 5(5):1111–1121
Esposito D, Chatterjee DK (2006) Enhancement of soluble protein expression 
through the use of fusion tags. Curr Opin Biotechnol 17(4):353–358
Guo C, Huang Y, Zheng H, Tang L, He J, Xiang L et al (2012) Secretion and activ-
ity of antimicrobial peptide cecropin D expressed in Pichia pastoris. Exp 
Ther Med 4(6):1063–1068
Hong IP, Lee SJ, Kim YS, Choi SG (2007) Recombinant expression of human 
cathelicidin (hCAP18/LL-37) in Pichia pastoris. Biotechnol Lett 29(1):73–78
Jimenez JJ, Borrero J, Gutiez L, Arbulu S, Herranz C, Cintas LM et al (2014) Use 
of synthetic genes for cloning, production and functional expression of 
the bacteriocins enterocin A and bacteriocin E 50-52 by Pichia pastoris 
and Kluyveromyces lactis. Mol Biotechnol 56:571–583
Kant P, Liu WZ, Pauls KP (2009) PDC1, a corn defensin peptide expressed in 
Escherichia coli and Pichia pastoris inhibits growth of Fusarium gramine-
arum. Peptides 30(9):1593–1599
Kim SJ, Quan R, Lee SJ, Lee HK, Choi JK (2009) Antibacterial activity of recom-
binant hCAP18/LL37 protein secreted from Pichia pastoris. J Microbiol 
47(3):358–362
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the 
head of bacteriophage T4. Nature 227(5259):680–685
Li Y (2009) Carrier proteins for fusion expression of antimicrobial peptides in 
Escherichia coli. Biotechnol Appl Biochem 54(1):1–9
Mattanovich D, Callewaert N, Rouzé P, Lin Y-C, Graf A, Redl A et al (2009) Open 
access to sequence: browsing the Pichia pastoris genome. Microb Cell 
Fact 8:53
Mulder KCL, Lima LA, Miranda VJ, Dias SC, Franco OL (2013a) Current scenario 
of peptide-based drugs: the key roles of cationic antitumor and antiviral 
peptides. Front Microbiol 4:321
Mulder KCL, Viana AAB, Xavier X, Parachin NS (2013b) Critical Aspects to be 
considered prior to Large-Scale Production of peptides. Curr Protein Pept 
Sci 14:556–567
Parachin NS, Mulder KC, Viana AA, Dias SC, Franco OL (2012) Expression 
systems for heterologous production of antimicrobial peptides. Peptides 
38(2):446–456
Saúde AC, Ombredane AS, Silva ON, Barbosa JA, Moreno SE, Araujo AC et al 
(2014) Clavanin bacterial sepsis control using a novel methacrylate nano-
carrier. Int J Nanomed 9:5055–5069
Silva ON, Mulder KC, Barbosa AE, Otero-Gonzalez AJ, Lopez-Abarrategui C, 
Rezende TM et al (2011) Exploring the pharmacological potential of 
promiscuous host-defense peptides: from natural screenings to biotech-
nological applications. Front Microbiol 2:232
Silva ON, Migliolo L, Dias SC, Rezende TMB, Franco, OL (2011b) Patent: Anti-
microbial, insecticide and antitumor synthetic molecule, composition, 
use and microorganism inhibition method. INPI, Brazil Patent Number 
0000221109717908
Silva ON, Fensterseifer ICM, Rodrigues EA, Holanda HHS, Novaes NRF, 
Cunha JPA et al (2015) Clavanin A improves outcome of complica-
tions from different bacterial infections. Antimicrob Agents Chemother 
59(3):1620–1626
Song X, Wang J, Wu F, Li X, Teng M, Gong W (2005) cDNA cloning, functional 
expression and antifungal activities of a dimeric plant defensin SPE10 
from Pachyrrhizus erosus seeds. Plant Mol Biol 57(1):13–20
Tang XS, Tang ZR, Wang SP, Feng ZM, Zhou D, Li TJ et al (2012) Expression, puri-
fication, and antibacterial activity of bovine lactoferrampin–lactoferricin 
in Pichia pastoris. Appl Biochem Biotech 166(3):640–651
Towbin H, Staehelin T, Gordo J (1979) Electrophoretic transfer of proteins 
from polyacrylamide gels to nitrocellulose sheets: procedure and some 
applications. Biotechnol Adv 24:145–149
van Kan EJ, van der Bent A, Demel RA, de Kruijff B (2001) Membrane activity 
of the peptide antibiotic clavanin and the importance of its glycine 
residues. Biochemistry 40(21):6398–6405
Page 8 of 8Mulder et al. AMB Expr  (2015) 5:46 
van Kan EJ, Demel RA, Breukink E, van der Bent A, de Kruijff B (2002) Clavanin 
permeabilizes target membranes via two distinctly different pH-depend-
ent mechanisms. Biochemistry 41(24):7529–7539
van Kan EJ, Demel RA, van der Bent A, de Kruijff B (2003a) The role of the 
abundant phenylalanines in the mode of action of the antimicrobial 
peptide clavanin. Biochim Biophys Acta Protein Struct Mol Enzymol 
1615(1–2):84–92
van Kan EJ, Ganchev DN, Snel MM, Chupin V, van der Bent A, de Kruijff B 
(2003b) The peptide antibiotic clavanin A interacts strongly and specifi-
cally with lipid bilayers. Biochemistry 42(38):11366–11372
Varnai A, Tang C, Bengtsson O, Atterton A, Mathiesen G, Eijsink VG (2014) 
Expression of endoglucanases in Pichia pastoris under control of the GAP 
promoter. Microb Cell Fact 13(1):57
Viragh M, Voros D, Kele Z, Kovacs L, Fizil A, Lakatos G et al (2014) Production of 
a defensin-like antifungal protein NFAP from Neosartorya fischeri in Pichia 
pastoris and its antifungal activity against filamentous fungal isolates 
from human infections. Protein Expr Purif 94:79–84
Waterham HR, Digan ME, Koutz PJ, Lair SV, Cregg JM (1997) Isolation of the 
Pichia pastoris glyceraldehyde-3-phosphate dehydrogenase gene and 
regulation and use of its promoter. Gene 186(1):37–44
Yu R, Dong S, Zhu Y, Jin H, Gao M, Duan Z et al (2010) Effective and stable 
porcine interferon-alpha production by Pichia pastoris fed-batch cultiva-
tion with multi-variables clustering and analysis. Bioprocess Biosyst Eng 
33(4):473–483
Zhang AL, Luo JX, Zhang TY, Pan YW, Tan YH, Fu CY et al (2009) Recent 
advances on the GAP promoter derived expression system of Pichia 
pastoris. Mol Biol Rep 36(6):1611–1619
Zhao P, Cao G (2012) Production of bioactive sheep beta-defensin-1 in Pichia 
pastoris. J Ind Microbiol Biotechnol 39(1):11–17
